Credo Diagnostics will be present at Medical Japan Osaka in February 2022
Taiwan – Credo Diagnostics will be present at Medical Japan Osaka in February 24-26, 2022. Please come and visit our booth! Medical Japan is Japan’s leading trade show consisting of specialized shows for the Medical, Elderly Care and Pharmacy industries. The show will exhibit Medical IT, IT systems for hospitals, medical/hospital supplies, disposables, medical equipment, […]
VitaPCR™Sample Collection Buffer Shows the Capability of Inactivating the SARS-CoV-2 Virus, Influenza A Virus, Influenza B Virus, and Respiratory Syncytial Virus (RSV)
Taiwan, January 14, 2022–SARS-CoV-2, Influenza virus, and Respiratory syncytial virus (RSV) are the well-known pathogens responsible for several contagious respiratory diseases, which can cause mild to severe illness and even death. These pathogens can spread very quickly from person to person, simply by touching or breathing in virus-containing particles. A case in point is COVID-19, […]
Credo VitaPCR™ system is on board! To work with Explorer Dream to resume cruises in Taiwan
Taiwan – Credo Diagnostics, a leader in the development of advanced MedTech diagnostics solutions, is proud to announce that we have successfully installed 6 VitaPCR™ Instruments on the cruise ship Explorer Dream (探索夢號). By providing a true Point-of-Care and accurate molecular diagnostic solution based on the real-time Polymerase Chain Reaction (real-time PCR) technology, cruise tours […]
Credo Diagnostics nabs CE mark for VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets
Taiwan, January 10, 2022 –Credo Diagnostics Biomedical Pte. Ltd. is delighted to announce that both VitaPCR™ Flu A/B and VitaPCR™ RSV external control sets have obtained the CE IVD mark. These control sets are intended to be used for quality control testing with a series of VitaPCR™ Assays (exclude VitaPCR™ SARS-CoV-2 Assay, Cat# PCRAE0114) VitaPCR™ […]
VitaPCR™ sample collection buffer can inactivate SARS-CoV-2 effectively
Taiwan, January 7, 2022 –For all diagnostic procedures to test COVID-19, performing these tests at POC or near-POC requires a suitable and sufficient risk assessment and implementation of appropriate control measures. It is essential that the rapid testing procedure, which may involve swab stirring/mixing into an elution buffer with the potential for associated generation of […]
The establishment of Credo Diagnostics Biomedical Pte. Ltd. Taiwan Branch for delivering the highest quality medical solutions
Taiwan, January 1, 2022 –It is with great pleasure that we announce the establishment of our Branch in the Republic of China, Taiwan. This important milestone comes as part of our continuous efforts to expand our reach and make our products and services as widely available as possible. Importantly, this initiative continues our focus, ADVANCED […]
Credo Diagnostics is proud to be one of the Top 50 Healthcare Startups in Singapore!
Credo Diagnostics is proud to be on the list of “Top 50 Healthcare Startups in Singapore” published by StartupLanes. We vow to accelerate the molecular test and provide it at an affordable cost. Being on the list of Top 50 Healthcare Startups is a great reward to our efforts and our pursuit to the mission […]
Credo VitaPCR™ SARS-CoV-2 RNA detection Assay can correctly detect the new Omicron strain B.1.1.529 BA.1 and its sublineage BA.2 (stealth version)
In response to the new Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on December 17th, 2021. According to our analysis, we confirm that our SARS-CoV-2 RNA detection […]
The Change of Address
Singapore, December 1, 2021 – Credo Diagnostics Biomedical Pte Ltd changes registered address to: 491B RIVER VALLEY ROAD, #06-01 VALLEY POINT, SINGAPORE (248373)
Analysis Shows Credo’s VitaPCR™ SARS-CoV-2 Related Assays are capable of detecting the new variant strain Omicron Variant correctly
In response to the new variant strain Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on November 29th, 2021. According to our analysis, we confirm that our SARS-CoV-2 […]
